Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 July 1999Website:
http://www.biomarin.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 63 min agoDividend
Analysts recommendations
Institutional Ownership
BMRN Latest News
BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth.
SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.
UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
What type of business is BioMarin Pharmaceutical?
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative treatments for people with serious and life-threatening rare diseases and medical conditions. BioMarin was founded in 1996 and is headquartered in San Rafael, California. The company's portfolio includes several commercial products and several clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Aldurazyme - a drug for the treatment of the genetic disease mucopolysaccharidosis; Brineura - a drug for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, also known as Batten disease; and Kuvan (tetrahydrobiopterin) - a patented synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disorder; among others.
What sector is BioMarin Pharmaceutical in?
BioMarin Pharmaceutical is in the Healthcare sector
What industry is BioMarin Pharmaceutical in?
BioMarin Pharmaceutical is in the Biotechnology industry
What country is BioMarin Pharmaceutical from?
BioMarin Pharmaceutical is headquartered in United States
When did BioMarin Pharmaceutical go public?
BioMarin Pharmaceutical initial public offering (IPO) was on 26 July 1999
What is BioMarin Pharmaceutical website?
https://www.biomarin.com
Is BioMarin Pharmaceutical in the S&P 500?
No, BioMarin Pharmaceutical is not included in the S&P 500 index
Is BioMarin Pharmaceutical in the NASDAQ 100?
No, BioMarin Pharmaceutical is not included in the NASDAQ 100 index
Is BioMarin Pharmaceutical in the Dow Jones?
No, BioMarin Pharmaceutical is not included in the Dow Jones index
When was BioMarin Pharmaceutical the previous earnings report?
No data
When does BioMarin Pharmaceutical earnings report?
The next expected earnings date for BioMarin Pharmaceutical is 21 February 2025